Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) shares shot up 1.6% during trading on Thursday. The stock traded as high as $3.21 and last traded at $3.13. Approximately 284,344 shares changed hands during mid-day trading, an increase of 9% from the average session volume of 261,100 shares. The stock had previously closed at $3.08.
Aadi Bioscience Stock Performance
The firm has a 50-day moving average of $3.44 and a 200-day moving average of $3.84. The firm has a market capitalization of $75.82 million, a P/E ratio of -1.35 and a beta of 0.68.
About Aadi Bioscience
Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing therapies for cancers associated with specific genetic alterations. Its work has centered on precision medicines intended for patients with rare or difficult-to-treat tumors. The company’s lead product is FYARRO, an albumin-bound formulation of sirolimus. In the United States, FYARRO is approved for adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, a rare cancer also known as malignant PEComa.
Further Reading
- Five stocks we like better than Aadi Bioscience
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
